KLRK1 and cancer: Several studies have shown that soluble NKG2D-ligands derived from cancer cells by alternative splicing [19], proteolytic shedding [20,21,22,23], or exosome secretion [24] can impair NKG2D-mediated cytotoxicity by negatively regulating NKG2D surface expression.